Who is the CEO of 4D pharma plc?

Mr. Duncan Joseph Peyton is a business executive who currently serves as the CEO of 4D pharma plc.

What is the Revenue Growth of 4D pharma plc?

Revenue growth data for 4D pharma plc is currently unavailable.

What is 4D pharma plc operating Margin?

Operating margin data for 4D pharma plc is currently unavailable.

In which market sector does 4D pharma plc operate?

4D pharma plc falls under the Healthcare sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is 4D pharma plc revenue growth?

Revenue growth data for 4D pharma plc is currently unavailable.

4D pharma plc

LBPSW•NASDAQ

HealthcareBiotechnology

$0.04

$0.04(14.81%)

4D pharma plc (LBPSW) Stock Overview

Explore 4D pharma plc’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for LBPSWStats details for LBPSW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for LBPSWAnalyst Recommendations details for LBPSW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company's development programs include Blautix for irritable bowel syndrome and Thetanix for paediatric crohn's disease. It also develops immuno-oncology products comprising MRx0518, MRx0573, and MRx1299 for solid tumors, and MRx0518 for pancreatic cancer; respiratory products, such as MRx-4DP0004 for asthma and COVID-19; central nervous system products, including MRx0005 and MRx0029 for neurodegeneration; and platform products comprising vaccines and autoimmune. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumours. The company was formerly known as Schosween 18 Limited. 4D pharma plc was founded in 2014 and is headquartered in Leeds, the United Kingdom.

CEO

Mr. Duncan Joseph Peyton

Employees

127

Headquarters

9 Bond Court, Leeds

Founded

2021